• Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate
• The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns
• Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan
• The DEA recently recommended a significant increase in cannabis and psilocybin use in medical science research, and the White House has asked Congress to consider changing drug legislation to better address the use of those drugs in clinical research

Two years after the U.S. Food and Drug Administration (“FDA”) declared the hallucinogenic substance psilocybin a “breakthrough therapy” to speed the process of the drug’s scientific clinical trials and reviews (https://ibn.fm/umfbQ), Michigan continues to cement its reputation as a hotbed for medicinal psychedelics advocacy and research, and proponents there believe society has reached a watershed moment for the substances’ acceptance. Law enforcement officials in the state’s Ann Arbor region have effectively decriminalized natural compounds with hallucinogenic properties deemed illegal under state and federal law (although not synthetic compounds such as LSD), and last month Ann Arbor’s City Council voted 10-0 to declare September “Entheogenic Plant and Fungi Awareness Month.” As a result, the city will celebrate a “sacred plant and mushroom festival” called Entheo Fest every September, beginning Sept. 19 (https://ibn.fm/1UXcX). The decisions highlight a growing cultural shift not unlike the transformation of cannabis’ stigma to a general acceptance of marijuana’s potential for therapeutic and recreational use when produced under quality constraints by recognized business enterprises in recent years. Earlier this month, the Drug Enforcement Administration (“DEA”) proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medications (https://ibn.fm/6t5FB). The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogenic substances are regulated (https://ibn.fm/dWPuE). San Diego-based Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on novel bioscience solutions for medical conditions with unmet needs, specifically oriented toward developing its synthetic psilocybin candidates through clinical trials that target chronic pain and select eating disorders. The company expects to soon launch a Phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome (“PWS”), hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder. TRP-8802 will be used in combination with psychotherapy under professional care. “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders,” Dr. Jennifer Miller, the trial’s principal investigator, stated during an interview with The Dales Report in May (https://ibn.fm/7eX83). “Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the company added in a news release last month (https://ibn.fm/ljJmr). “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders”. Tryp Therapeutics then plans to proceed into Phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure
• Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant”
• Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure
• These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment

Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure (“BP”) over a 24-hour ambulatory period. The results, referred to as “Statistically significant” by Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, inched the company closer to an eventual New Drug Application (“NDA”) (https://ibn.fm/pDUHy). The study involved volunteers getting three doses of 150 mg of DehydraTECH CBD over 24 hours, spanning both sleep and wake cycles of activity. Participants coping with mild to moderate hypertension reported up to an impressive average 23% decrease in blood pressure, relative to placebo, during the 24 hours. The study also showed that these individuals averaged a 7% drop in systolic pressure. Upon further analysis of the results, it was established that each of the three doses resulted in a slightly lower blood pressure level than the trough, which is usually the lowest concentration reached by a drug before the next dose is administered. This was mainly apparent during the quiet hours of sleep when most individuals are more prone to cardiac events. When making the announcement, Mr. Bunka noted: “Our 2018 study showed a slight reduction in blood pressure, but it was not awe-inspiring. This time, the average drop in blood pressure is larger, and it appears that the sequential doses are additive. We’ll investigate that further.” This clinical trial and the results from the study so far have prompted Lexaria into beginning an Investigational New Drug Application (“NDA”) filing with the FDA. The company plans to make the application, listing DehydraTECH CBD as a prospective registered pharmaceutical treatment for hypertension. DehydraTECH CBD is already patent granted in both the EU and in Australia, for treating heart disease. Going forward, Lexaria expects to stay consistent with its studies, with the hope of showing more positive results. The goal is to leverage both internal and external data on the effectiveness of DehydraTECH and even to possibly use the abbreviated 505(b)(2) NDA application to speed up timelines for approval. “If we can sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market,” noted Mr. Bunka. “Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects,” he added. Lexaria is currently focusing on undertaking the requisite procedures, having already established commercial success with its technology. Shareholders are optimistic about the company’s future, and for a good reason. The strides that Lexaria has made so far have brought it even closer to its DehydraTECH approval for hypertension treatment and management. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Date: Sept. 21-22, 2021 Virtual event Free registration Investors and traders are invited to attend the ETF Investing Canada Virtual Expo organized by MoneyShow on September 21-22, 2021. MoneyShow is trusted by millions of investors and traders for its global network of investing and trading experts The company is engaged in hosting award-winning in-person conferences, virtual events, and timely content online where industry experts offer their valuable insights on the current and future investment trends. With investors and traders increasingly using ETFs in their portfolios, this investment vehicle is attracting billions of dollars from the global financial ecosystem. However, with hundreds of different products available, this makes it difficult for investors to select the right solution for their portfolio. At the ETF Investing Canada Virtual Expo, attendees will learn and gain knowledge from ETF industry stalwarts and portfolio managers, who will offer effective ETF strategies and help gain market exposure so that traders can implement the right investment techniques to build a strong ETF portfolio. Canada’s top ETF experts will suggest investment opportunities that will guide investors and traders to identify assets classes and sectors that are poised to outperform in the upcoming months. This live streaming event offers fresh insights, strategies, and tips on how to maximize gains from shifts in a post-Covid arena and build a robust portfolio with ETFs. Attendees will

• Attend the live sessions, get sound ETF portfolio recommendations and picks from the experts, and learn the latest tips and trends for investing and trading.
• Visit the virtual booths to understand the latest investment strategies and get educational content about the products from top companies while watching their corporate videos.
• Interact and learn from the industry experts via live chats and message boards to answer all your queries regarding ETF investments and trading.

Watch this virtual event free to learn the intricacies of investment from the 35 leading ETF experts namely Larry Berman, Partner and Chief Investment Officer, ETF Capital Management who will discuss the future of balanced portfolios. Investors and traders will learn tips to manage and adapt their portfolios to current market situations. They will also understand timely recommendations on ETFs, which ranges from actively managed to buffered, leveraged, non-equity, smart beta, thematic, and more. Also, attendees will get in-depth information about the latest research and analysis for investors and traders, educational videos and articles. They can also get exclusive discounts and win great prizes in the Virtual Exhibit Hall that will feature numerous leading global financial product-and-service providers. For more information, please visit https://ibn.fm/4z1Iy.

• Roth Capital Partners will host the “Women Cannabis Pioneers – The Brand Builders” event on September 28, 2021
• The conference is set to feature approximately 25 privately held and female-led companies operating within the North American cannabis market
• Institutional investors will have an opportunity to discover new investment opportunities through their interaction with a host of emerging and lesser-known privately held companies

Hosted by Roth Capital Partners (“Roth”), a widely respected independent securities research and trading firm specializing in emerging growth companies, the Investing in Women Cannabis Pioneers – The Brand Builders event has been uniquely designed to highlight the cannabis industry with a distinct perspective. Renowned for hosting some of the nation’s largest conferences across a variety of different equity sectors, Roth Capital Partners has partnered with Wendy A. Berger, founder of Woman Backing Women, LLC, to provide investors with the opportunity to listen to, learn from, and interact with some of the leading, female-led private companies in a truly unique event. A study carried out by Forbes magazine revealed that American women held nearly 27 percent of the leadership roles within the legal cannabis industry, a significant increase relative to their positions within traditional industries (https://ibn.fm/D5A6X). The upcoming conference will enable the institutional investors in attendance to meet with the executive management teams of approximately twenty-five of the most innovative and ground-breaking female-led private companies operating within the cannabis sector today. Featuring a broad array of companies, ranging from established corporations with a strong reputation across private markets to recent start-ups developing their initial product lines, the event will play host to companies currently operating within a multitude of cannabis sub-sectors, including edibles, beverages, dispensaries & distribution, topicals & tinctures, and vaping. A full list of participating companies can be found here: https://ibn.fm/NsG9A The conference will also include three distinct and enlightening industry panels: 1:00 PM (ET) / 10:00AM (PT): “Investing in Women-Owned Cannabis Brands” Summary: Keys to building leading cannabis brands/companies for long-term success and M&A opportunities. Explores the challenges women face in the cannabis industry at the Board/C-Suite level, capital raising and corporate governance. Participants: Moderated by Wendy Berger, Green Thumb Industries – Board Director. Presenters include Jen Drake, AYR Strategies (OTC: CNBQF) – Co-Chief Operating Officer; Deanie Elsner, Charlotte’s Web Holdings (TSX: CWEB) – Chief Executive Officer; Laurie Holcomb, Gold Flora – Chief Executive Officer; Jill Scher, Marcum – Partner; Eliza Gairard, Richmond Hill – Partner; Kim Rivers, Trulieve Cannabis (OTCQX: TCNNF) – Chief Executive Officer. 1:40 PM (ET) / 10:40 AM (PT): “Women Cannabis Consumption and Brands” Summary: Panel discussion includes data analyzing women as the fastest-growing cannabis consumer. The panel will explore women buying patterns, product formats, targeting women, and innovation to meet the demand of the female consumer. Participants: Moderated by Liz Connors, Headset – VP of Data & Analytics. Presenters include Salpy Boyajian, Flower One Holdings (OTCQX: FLOOF) – Executive Vice President & Board Chairman; Kristi Palmer, Kiva – Founder; Evelyn Wang, Papa & Barkley – Chief Executive Officer; Nancy Whiteman, Wana – Chief Executive Officer. 2:20 PM (ET) / 11:20 AM (PT): “Building Brands Nationally Across State Lines” Summary: Panel discussion includes expanding leading brands across state lines, navigating manufacturing/distribution partnerships, and state regulatory differences for various product formats. Explore establishing IP and brand protection. Participants: Moderated by Sarah Robertson, Dorsey & Whitney LLP – Partner. Presenters include Jamie Pearson, Bhang Cannabis – President/CEO; Amasa Lacy, Hollister Cannabis – Vice President of Production and Co-Founder; Yoko Miyashita, Leafly – CEO; Denise Faltischek, Tilray (NASDAQ: TLRY) – Head of International and Chief Strategy Officer. Investment data has habitually revealed that women-helmed companies feature higher business metrics than those run by men (https://ibn.fm/qTc6s). In a similar vein, Roth Capital Partners’ Women Cannabis Pioneers – The Brand Builders event, in conjunction with Wendy A. Berger, will shed light on a relatively undiscovered yet rapidly growing segment of the North American cannabis market. For more information about the upcoming Roth conference, visit https://www.roth.com/womenincannabis About Roth Capital Partners Roth Capital Partners, LLC (“Roth”) is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, Roth is privately held and employee owned. For more information on Roth, please visit www.Roth.com.

• Robin Mackie new President of Ideanomics Mobility, as of September 8, 2021
• Mackie will help the company to make the most out of its acquisitions, driving growth on its path to a zero-emission future
• He will also help Ideanomics expand its global talent pool to further develop its key advantage as a global provider of EV mobility solutions
• Mackie brings a wealth of knowledge and decades of experience in the EV sector

On September 8, 2021, Ideanomics (NASDAQ: IDEX) announced the appointment of Robin Mackie as the new President of Ideanomics Mobility. Before he was appointed President, Mr. Mackie served as a consultant for the company for six months, proving his value to its growth and achieving its set goals and objectives (https://ibn.fm/x6i7u). When making the announcement, Alf Poor, the Chief Executive Officer (“CEO”) of Ideanomics, noted: “Robin has proven to be a driving force in his recent consulting role for Ideanomics Mobility. Bringing him onto our internal team in a leadership capacity will help us to expand our already impressive global talent pool, as well as help us further develop our strategic advantage as a global provider of EV mobility solutions.” Mr. Mackie brings over three decades of experience in engineering, operations, and global design in different highly regulated industries, including offshore, construction, and automotive. He has served in different roles, including engineering and development director at Express Group, the President and Chief Technology Officer (“CTO”) of Smith Electric Vehicles, before ultimately starting his consulting business in 2017 (https://ibn.fm/RUN1q). While confirming his appointment, Mr. Mackie noted: “Throughout my more than 30 years in business, I have worked with mobility companies around the globe, and I am thrilled to bring my knowledge and experience to the team at Ideanomics. I am passionate about energy, sustainability, and transportation, all which combine to make this a perfect fit as I step in to lead this division during a period of unprecedented growth for both Ideanomics and the EV industry as a whole.” Ideanomics Mobility is a division of the parent company that offers access to industry-leading products and services across vehicle procurement, charging infrastructure, and energy management, primarily through a suite of EV-specific subsidiaries. This division has landed over $1 billion in acquisitions in the past year alone, including VIA Motors’ proposed acquisition for up to $620 million. It is acquisitions such as these that allow Ideanomics Mobility to offer unrivaled services in the industry. Having Mr. Mackie on board would allow the company to make the most out of these attainments, realize its potential and drive growth on its path to a zero-emission future. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• The company will be utilizing Amazon’s fulfillment services, customer service, and network of affiliates in the U.S. and Canada
• The Amazon platform will also feature PlantX-label plant-based brands and products for sale
• The overall PlantX platform features a one-stop shop for all things plant-based, including grocery, meal delivery, The Plant Shop, weekly recipes, and more
• The company is preparing to begin NCIB on or around September 15, 2021, through September 14, 2022. The shares represent approximately 5% (6,071,757) of the common shares available for purchase.
• Through PI Financial Corp., the company will make the purchase of the common shares for cancelation as they feel their value as a company is underrepresented based on these shares
• An additional purchase of common shares is expected to be initiated by Executive Chairman Fred Leigh up to 5% of the common share available

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is moving closer to redefining the plant-based community by becoming the most trusted and convenient destination online for people living plant-based lives. PlantX has recently announced that it will be launching as a Seller on the Amazon Marketplace. The company will launch both Canadian and U.S. online stores, list and sell plant-based products, and fulfill customer orders. This strategic e-commerce maneuver will allow PlantX to utilize Amazon’s fulfillment services, customer service, and network of affiliates (https://ibn.fm/Vtt0M). “Launching on the Amazon platform is a great opportunity to boost access to our plant-based brands and products. We are particularly excited about adding PlantX private label products to this new platform,” PlantX Founder Sean Dollinger said. “We believe it will increase our impact as we expand our in-house brands.” PlantX’s platform is positioned to serve as the digital face of the plant-based community, providing a one-stop-shop for everything “plant,” including an easy-to-use e-commerce experience that features:

• Plant-based grocery items – from pantry needs to vitamins, cosmetics, pet food, and more
• Meal delivery with recipes from renowned plant-based chefs from around the world
• The Plant Shop – delivering indoor, household plants to homes across Canada and the US
• Weekly, easy-to-follow plant-based recipes
• Partnerships with restaurants, nutritionists, chefs, and other brands
• Access to a community of like-minded individuals

In addition to the online presence, PlantX connects with consumers through the brick-and-mortar store locations and home delivery – primarily focuses on consumer-packaged goods (“CPGs”) with plant-based opportunities. The company is also planning to commence a normal course issuer bid (“NCIB”). An NCIB is a strategic move where a company purchases a percentage of its issued and outstanding common shares. In the case of PlantX, the company plans to purchase the equivalent of 5% (6,071,757) of the available common shares because it believes that the market price may not fully reflect the underlying value of the business or its future prospects. PlantX believes purchasing and canceling these common shares is an appropriate use of financial resources that will ultimately enhance shareholder value (https://ibn.fm/jW8QQ). In addition to the company’s common stock purchase, Executive Chairman Fred Leigh also intends to purchase up to 5% of PlantX’s issued and outstanding common shares on the open market through the CSE facilities.  PlantX’s NCIB is expected to take place on or around September 15, 2021, terminating on or around September 14, 2022, with all common shares purchased under the NCIB on the open market through the CSE. PlantX plans to execute the plan through PI Financial Corp., a broker it has enlisted to handle the NCIB on behalf of the company. Every common share purchased will be done so for cancellation. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• U.S.-based FingerMotion is a mobile phone services and emerging big data technology company focused on the enormous prospects of China’s marketplace
• FingerMotion’s drive to develop its new Sapientus database IP has led to a significant agreement for providing big data to global insurance juggernaut Pacific Life’s Reinsurance division
• Pacific Life is among a number of outsider companies looking to enter China’s marketplace, and FingerMotion’s data is expected to help the company establish risk prediction profiles for its clientele
• China boasts a population of about 1.4 billion people, of whom more than half have adopted mobile phone technology during the past quarter century as the country’s economy has made great strides forward
• An estimated 989 million Chinese citizens have adopted Internet use and e-commerce as a part of their lifestyle

Given current estimates that China’s population will surpass 1.4 billion people this year, occupying a land mass larger than the United States while building one of the world’s fastest growing economies, it’s no surprise that China has repeatedly occupied a position as the most attractive marketplace in the world during recent years (https://ibn.fm/aswHa). Corporations developing their growth strategies continually freshen their outlooks on the benefits of entering China’s market while weighing any challenges that might be unique to the country, particularly in terms of technological development. But great leaps in Internet and satellite-based communications within the country are helping to drive new confidence in the potential for consumer acquisition and responsiveness. Of note, China’s mobile phone users have increased during the past quarter century from about 3.6 million people to about 986 million, or more than half the country (https://ibn.fm/Kg4tm),  while Internet users have increased from 60,000 people to 989 million (https://ibn.fm/jq2Qc). Evolving technological services company FingerMotion (OTCQX: FNGR) is focused on the development and monetization of communications-related services in China, particularly in exploring the potential of big data and analytical technology to help other companies thrive in the country’s economy. FingerMotion is a U.S.-based company is building a communications ecosystem of active users based on its flagship Sapientus database IP, a predictive services solution that has led to a landmark agreement with Pacific Life Re-insurance as the world-leading insurance juggernaut adds Chinese clients’ needs to its operational infrastructure. FingerMotion anticipates that it may eventually use Sapientus’ capabilities to provide solutions for other market sectors as well, including predictive risk assessments for health care, financial services and consumer e-commerce applications. In June, CEO Martin Shen noted that the relatively new establishment of the company’s Big Data Insights division led to its first revenues during the previous fiscal year and expectations of greater profits during the current year. “We are a technology company and believe our future lies in the Big Data Insights division. By the end of calendar 2021, we expect multiple contracts relating to our Insuretech products,” he reported (https://ibn.fm/matjH). Shen said the company also believes it has taken significant steps toward meeting the qualifications for listing with senior exchanges as its shareholder equity continues to show a healthy response, ending the previous year at $2.11 million. Mobile payment and recharge platform solutions, where its core competency lies, has boosted the company to a level where it handles over 500,000 transactions every day for those services. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Flora also recently announced it had received its 2021 commercial export quota allocation of 7,900 kilograms to cultivate, process, and distribute high-THC cannabis
• Flora Growth also announced it has entered into an agreement with Applied DNA Sciences, Inc. and TruTrace Technologies, Inc.
• FLGC will deploy the two companies’ integrated technology as part of its global cannabis product validation and authentication platform
• The integrated technology will tag, test, and track Flora’s cannabis and cannabis derivative products during transit across an international supply chain, providing enhanced transparency, traceability, and trust

As an internationally focused company, Flora Growth (NASDAQ: FLGC) has always strived to build a global cannabis consumer packaged goods (“CPG”) portfolio by leveraging natural, low-cost cultivation practices; developing products that positively impact the health and wellness of people; and growing a global footprint through partnerships, investments, and acquisitions. In line with this commitment, Flora recently entered into distribution agreements with Kiricann (https://ibn.fm/Q8K4e) and Evergreen Pharmacare (https://ibn.fm/whN6l) to supply dried flower and derivatives to Africa and the EU, as well as Australia, adding to its existing strategic global growth and distribution initiatives. Coming shortly after the Colombian government announced reformed, more accessible cannabis legislation, Flora recently announced it had received its 2021 export quota from the Columbian Technical Quotas Group (“TQG”) to cultivate, process, and distribute up to 7,900 kilograms of high-THC cannabis dried flower (https://ibn.fm/f1Ftj). The company believes the allocated export quota will be sufficient to meet the international demand for its product throughout the remainder of the year and the beginning of 2022. This export quota allocation, coupled with the distribution agreements with Kiricann and Evergreen and the €2 million investment in Hoshi International, closed August 24 (https://ibn.fm/hbCNN), is a significant milestone for the company. According to Warnock, it represents a major opportunity to export Flora’s high-margin, high-THC goods to legal markets around the world. Nonetheless, Flora is not just prioritizing planting the new high-THC cultivars but is also actively harvesting its high-CBD crops, with the harvest expected to create a robust pipeline of cannabis derivatives for the company to use across its premium brands and products, as well as for export. As part of the preparations towards the expected export of cannabis and cannabis products via the two distributors, Flora announced September 8 that it has partnered with Applied DNA Sciences, Inc. (NASDAQ: APDN) and TruTrace Technologies, Inc. (OTC: TTTSF) with the aim of establishing a new global standard for cannabis distribution practices (https://ibn.fm/bieU8). Under the terms of the Master Services Agreement (“MSA”), Flora will deploy an integrated technology that brings together Applied DNA’s CertainT(R) and TruTrace’s StrainSecure(TM) platforms as part of its global cannabis product validation and authentication platform. The integrated technology, which is the result of an agreement between APDN and TruTrace signed earlier this year (https://ibn.fm/2p1XY), will allow Flora’s cannabis and cannabis derivative products to be tagged with a unique molecular identifier and tested for the identifier’s presence during travels across an international supply chain using CertainT. The products will then be tracked using StrainSecure by uploading the data points collected through tagging and testing to a blockchain-based cloud database (https://ibn.fm/EwBld). “In today’s globalized market, supply chain provenance is becoming an increasingly important component for every major CPG company. This is particularly true for the cannabis industry, where concerns over the sale and distribution of products from the illicit market persist for businesses,” said Flora Growth’s Chief Revenue Officer, Jason Warnock. “Flora anticipates that the added assurance, efficiency, and transparency brought by these technologies will optimize our value proposition to customers, differentiate us from peers, and increase our sales opportunities.” According to Applied DNA and TruTrace, the integrated technology will provide enhanced transparency, traceability, and trust across Flora’s international supply chain and will be instrumental in today’s cannabis industry, currently seeking legitimacy as it gains global acceptance. The integrated technology, whose build-out is well underway, will ensure that the products supplied from Colombia and delivered to global customers are derived directly from Flora’s operations. The implementation will, therefore, significantly reduce any concerns regarding illicit market products or counterfeits. Flora’s management anticipates that the integration will be ready in time for use by global customers receiving products, such as Kiricann and Evergreen. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• AmpliTech Group Inc. was recently featured in a Simply Wall Street article that observed multiple instances of insider buying
• Insider buying demonstrates that insiders believe in the company and anticipate the value of its shares will increase
• AmpliTech received two follow-on orders in June and July and reported a 117% quarter-over-quarter revenue increase in Q2 2021
• The company is making strategic investments to position it for hyper-growth opportunities across several markets

A recent Simply Wall Street article on AmpliTech Group (NASDAQ: AMPG) observed that in the last 12 months, multiple insiders acquired the company’s stock in large numbers – but did not sell (https://ibn.fm/rM7mU). Known as insider buying, this practice typically demonstrates that insiders – people with inside knowledge of a public company – believe in the organization and anticipate the share’s value will increase. The article came just a few days after AmpliTech released financial results for the second quarter and the first six months of 2021. The results, along with crucial developments throughout the last year, suggest the factors that could spawn the expected increase in value. A company that designs, develops, and manufactures custom radio frequency components for different markets, AmpliTech was founded in 2002 by president and CEO Fawad Maqbool. Since then, it has built a strong reputation anchored on performance and quality and embodied by recent achievements. On February 17 this year, for instance, the company’s common stock commenced trading on NASDAQ in what the company’s website notes “will help take our products to a broader and more global customer base, bringing cutting-edge technology to the masses and improving everyday quality of life for us all” (https://ibn.fm/GVleu). Even so, the company is already enjoying long-term relationships with several global customers. On July 29, AmpliTech secured $0.5 million in follow-on orders for custom Low Noise Amplifiers (“LNAs”) for a global high-speed satellite broadband services provider. According to Maqbool, the customer recognizes the value of AmpliTech’s industry-leading performance and reliability to deliver data and communications unimpacted by environmental interference (https://ibn.fm/CsvDi). This order came a little over a month after it had announced June 24 a similar follow-on order for its LNA technology from a Fortune 500 global defense and aerospace customer (https://ibn.fm/QH8Fv). Following the June 24 announcement, Maqbool expressed pride in the fact that AmpliTech’s performance, quality, and return on investment of its solutions continued to earn repeat business from global leaders. Further, AMPG’s focus on quality has also seen it garner numerous Supplier Quality awards, including a Best Technology Award from one of the industry’s leading trade magazines. The company anticipates growing business activity as well as increased customer demand as the economy reopens. Already, according to Maqbool, the gradual return of customer prospects has had a positive effect on the company’s financials. “Our Q2 results reflect initial benefits of our significantly enhanced financial position and the gradual return of customer prospects to more normal planning and procurement activity for projects where our low noise amplifier solutions can deliver game-changing performance and ROI,” he stated. For the three months ended June 30, 2021, AmpliTech reported $1.02 million in revenue, up from $660,699 reported in Q2 2020, representing a 55% increase. It also increased 117% when compared to Q1 2021 results. Gross profit increased 52.5% to $344,623 in Q2 2021 up from $225,998 in Q2 2020, reflecting the increase in revenue (https://ibn.fm/qLzpB). According to Maqbool, the company is making strategic investments in product development, sales and marketing, and personnel and infrastructure to better position AmpliTech for hyper-growth opportunities seen across several markets, including the build-out of true 5G infrastructure, quantum computing, space exploration, and satellite communications (SATCOM). Grandviewresearch anticipates that the SATCOM market, estimated at $66.63 billion in 2020, will grow at a 9.8% CAGR from 2021 to 2028 to reach $137.63 billion (https://ibn.fm/nDH70).  It also projects that the global 5G infrastructure market, valued at $2.64 billion in 2020, will grow at a 49.8% CAGR from 2021 to 2028 (https://ibn.fm/OUtRD). The global quantum computing market is expected to grow from $472 million in 2021 to $1.77 billion in 2026, marking a 30.2% CAGR (https://ibn.fm/OHiFK). This projection is based on analysis by MarketsandMarkets, which has also published numerous market reports showing that multiple segments of the space exploration market will experience more than 15% CAGR during the forecast periods, which run until the mid-2020s (https://ibn.fm/iki3X). “AmpliTech has a rich history in the design of microwave amplifiers and components, including a wide variety of product lines, from LNAs and MPAs (Medium Power Amplifiers) to broadband telecom amplifiers for the microwave and fiber optic communication firms,” reads the company’s website. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Canada-based life sciences company Mind Cure Health is developing a synthetic form of the psychedelic drug ibogaine as part of its efforts to take a leading position in the burgeoning market for mental health therapies
• Psychedelics, strengthened by new clinical research driving scientific and legislative openness to the drugs’ possible benefits under controlled conditions, are overcoming stigmas   that arose from recreational use of the drug
• Mind Cure Health is developing a proprietary software-as-a-service (SaaS) platform known as iSTRYM to optimize the healing journey between patients and caregivers
• The company recently released its year-end financial report and an analysis outlining its activities as well as its renewed strategic focus on technology and research

Life sciences company Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) recently reported its financial results for the three and twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. The report notes the company’s milestones leading to provisional patent filings for its innovative software application that will be used to provide real-time data for patient care in harmony with Mind Cure’s focus on developing mental health solutions that use novel psychedelic therapies. “The strategy and infrastructure we have put in place over the past year positions the company well to continue the development and release of our digital therapeutics platform, iSTRYM, and to continue our research for psychedelics,” President and CEO Kelsey Ramsden said about the results (https://ibn.fm/z6tz8). “I would like to especially thank our investors for seeing and supporting the vision and execution at MINDCURE.” The company initially began the year developing a nootropic line of functional mushrooms and supplements, in line with the rising consumer use of cognitive enhancement nootropics to improve brain function (https://ibn.fm/qlH35). With the company’s renewed focus on its digital technology and research and development activities, MINDCURE announced in August it has discontinued the development of its nootropics line of products. “As our organization has grown and our bi-divisional technology and drug research strategy have been refined, we need to focus entirely on what we do best – creating advanced and proprietary technology for and drug research in psychedelics,” said Kelsey Ramsden. During the past decade, scientific research and promising clinical trials have begun to suggest that drugs such as LSD, magic mushrooms, DMT, a variety of “plant medicines” including ayahuasca, iboga, salvia and peyote, as well as related compounds like MDMA and ketamine may become recognized as game-changing ways to treat depression, PTSD and addiction. The mental health community has observed the research with enthusiasm (https://ibn.fm/4RxVL). Investors who no longer regard the cannabis industry as a risky pursuit are now moving smart capital behind psychedelics as the “next frontier” of therapeutic solutions. A recent report by Fortune magazine noted that when psychedelic medicine developer ATAI Life Sciences made its recent debut on the Nasdaq, shares surged by 40 percent on the first day of trading, driving the company to a valuation of $2.6 billion. The growing global need for effective mental health treatments, evolving legislation and regulation, and widely supportive public opinion are all helping to drive an increase in investment capital and creating projections that the psychedelic health care market could reach $10.75 billion in revenues by 2027, according to Fortune’s report (https://ibn.fm/TLMdk). Mind Cure’s devotion to building access to safe, science-based, evidence-backed psychedelic-assisted therapies globally includes a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research as the industry advances. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF